Table 1.
Patient characteristics
| Grade group 1 | Grade group 2 | Grade group 3 | Grade group 4 | Grade group 5 | P‐value | |
|---|---|---|---|---|---|---|
| Number of patients | 1116 | 444 | 163 | 83 | 81 | |
| Age at diagnosis (years) | 66.7 (67.0: 63.2–70.5) | 66.9 (67.1: 63.4–71.0) | 68.1 (68.8: 64.9–71.9) | 67.9 (68.0: 65.2–71.5) | 66.9 (67.1: 63.6–70.9) | 0.004 a |
| PSA level at diagnosis (ng/ml) | 5.2 (4.2: 3.2–5.9) | 7.7 (5.2: 3.6–8.0) | 10.4 (5.9: 4.3–11.1) | 16.1 (9.2: 4.8–16.2) | 15.5 (7.8: 5.3–15.6) | <0.001 a |
| Percentage of positive cores (%) | 29.9 (25.0: 16.7–33.3) | 43.0 (42.9: 28.6–57.1) | 51.6 (50.0: 28.6–57.1) | 51.6 (50.0: 33.3–71.4) | 59.9 (57.1: 42.9–85.7) | <0.001 a |
| All cribriform | 12 (1.1) | 81 (18.2) | 93 (57.1) | 46 (55.4) | 48 (59.3) | <0.001 b |
| Small cribriform/IDC | 12 (1.1) | 79 (17.8) | 77 (47.2) | 31 (37.3) | 34 (42.0) | <0.001 b |
| Large cribriform | 0 | 2 (0.5) | 16 (9.8) | 15 (18.1) | 14 (17.3) | <0.001 b |
| Radical prostatectomy | 385 (34.5) | 172 (38.7) | 60 (36.8) | 26 (31.3) | 19 (23.5) | 0.081 b |
| Radiotherapy | 391 (35.0) | 203 (45.7) | 86 (52.8) | 53 (63.9) | 58 (71.6) | <0.001 b |
| Endocrine treatment | 17 (1.5) | 13 (2.9) | 6 (3.7) | 2 (2.4) | 6 (7.4) | 0.006 b |
| Watchful waiting/active surveillance | 328 (29.4) | 61 (13.7) | 13 (8.0) | 3 (3.6) | 2 (2.5) | <0.001 b |
| Radiotherapy and endocrine treatment | 5 (0.4) | 6 (1.4) | 2 (1.2) | 1 (1.2) | 4 (4.9) | |
| Unknown | 1 (0.2) | |||||
| Prostate cancer‐specific deaths | 22 (2.0) | 27 (6.1) | 30 (18.4) | 20 (24.1) | 24 (29.6) | <0.001 b |
Mean (median, interquartile range) or n (%) total: N = 1887.
PSA, prostate‐specific antigen; IDC, intraductal carcinoma.
a
Kruskal–Wallis test.
b
Pearson's χ2 test.